Livestreaming Platform Supported by:

custom image custom image custom image

  0      0

32nd Annual North American Cystic Fibrosis Conference

P2--*Anti-inflammatories & Mucociliary Clearance Therapies in the Age of CFTR Modulators

Oct 19, 2018 9:00am ‐ Oct 19, 2018 10:00am


This plenary will review the effect of CFTR dysfunction and CFTR restoration on both inflammation and mucociliary clearance in individuals with CF. Current and future therapeutic strategies to address inflammation and mucociliary clearance will be discussed, as well as how these strategies have potential to benefit both those patients using CFTR modulators and those not eligible for modulators.

Learning Objectives:

  • Identify current strategies to develop new therapies that treat inflammation in cystic fibrosis.
  • Identify current strategies to develop new therapies that improve mucociliary clearance in cystic fibrosis.
  • Describe the impact of CFTR modulators on inflammation and mucociliary clearance and why continued development of therapies is needed.

Plenary Leader(s):

  • Felix Ratjen, M.D., Ph.D., Division Head of Respiratory Medicine

You must be logged in and own this session in order to post comments.